pandem
influenza
pandem
demonstr
global
health
threat
reassort
influenza
strain
herein
report
detail
analysi
plasmablast
monoclon
antibodi
respons
induc
pandem
infect
human
unlik
antibodi
elicit
annual
influenza
vaccin
neutral
antibodi
induc
pandem
infect
broadli
crossreact
epitop
hemagglutinin
ha
stalk
head
domain
multipl
influenza
strain
antibodi
cell
undergon
extens
affin
matur
base
observ
postul
plasmablast
produc
broadli
neutral
antibodi
predominantli
deriv
activ
memori
b
cell
specif
epitop
conserv
sever
influenza
strain
consequ
neutral
antibodi
broadli
reactiv
diverg
influenza
strain
suggest
paninfluenza
vaccin
may
possibl
given
right
immunogen
antibodi
gener
potent
protect
rescu
mice
lethal
challeng
pandem
antigen
distinct
influenza
strain
make
excel
therapeut
candid
influenza
strain
especi
highrisk
popul
immunosuppress
patient
elderli
influenzaspecif
plasmablast
persist
induc
throughout
infect
provid
rich
sourc
antivir
mab
b
cell
respons
examin
nine
patient
infect
pandem
influenza
viru
patient
vari
cours
sever
diseas
case
rang
mild
diseas
rapid
viral
clearanc
within
day
onset
symptom
sever
case
shed
viru
sever
week
requir
hospit
ventil
support
major
patient
treat
antivir
drug
diagnos
confirm
pandem
rtpcr
serolog
patient
neutral
titer
serum
antibodi
time
blood
collect
summari
clinic
patient
data
shown
tabl
major
sampl
obtain
around
onset
symptom
except
particularli
sever
case
sampl
done
symptom
onset
antigenspecif
plasmablast
appear
transient
peripher
blood
vaccin
influenza
vaccin
brokstad
et
al
bernasconi
et
al
sasaki
et
al
wrammert
et
al
kinet
appear
persist
ongo
infect
remain
unclear
analyz
magnitud
specif
plasmablast
respons
blood
sampl
taken
within
week
onset
clinic
symptom
pandem
influenza
viru
infect
use
virusspecif
elispot
assay
possibl
show
signific
number
pandem
plasmablast
blood
infect
patient
wherea
none
detect
cohort
healthi
volunt
fig
b
cell
also
readili
detect
sever
week
symptom
onset
sever
case
fig
c
illustr
total
iggsecret
cell
half
cell
produc
antibodi
bound
pandem
influenza
viru
moreov
plasmablast
specif
ha
occur
frequenc
virusspecif
cell
fig
c
specif
like
critic
protect
patient
also
rel
high
frequenc
plasmablast
form
antibodi
bound
past
season
influenza
strain
fig
c
recombin
ha
previou
annual
strain
base
overal
frequenc
pandem
cell
like
cell
bind
strain
overlap
popul
crossreact
none
induc
plasmablast
cell
bound
recombin
ha
strain
vaccin
find
demonstr
influenzaspecif
human
plasmablast
continu
gener
throughout
ongo
infect
fairli
high
proport
cell
make
antibodi
also
crossreact
previou
annual
influenza
strain
analyz
specif
breadth
neutral
capac
plasmablast
use
singlecel
pcr
amplifi
heavi
light
chain
variabl
region
gene
individu
hancock
et
al
center
diseas
control
report
estim
million
case
pandem
strain
caus
hospit
unusu
high
frequenc
sever
diseas
occur
younger
otherwis
healthi
patient
hancock
et
al
addit
rare
infect
avian
influenza
strain
human
close
mortal
rate
subbarao
joseph
emerg
zoonot
antigen
distinct
strain
combin
even
fraction
morbid
mortal
pandem
virus
would
dire
consequ
antibodi
play
key
role
protect
influenza
infect
vivo
puck
et
al
gerhard
et
al
luke
et
al
simmon
et
al
fact
littl
preexist
antibodi
titer
present
emerg
pandem
viru
viru
atyp
caus
sever
diseas
young
adult
illustr
import
comprehens
understand
b
cell
respons
antibodi
specif
induc
infect
influenza
viru
analyz
plasmablast
respons
induc
pandem
infect
gener
panel
monoclon
antibodi
mab
cell
analyz
characterist
detail
contrast
season
vaccin
show
major
neutral
antibodi
induc
infect
broadli
crossreact
recent
annual
strain
well
highli
pathogen
avian
strain
neutral
antibodi
bound
predominantli
conserv
epitop
hemagglutinin
ha
stalk
region
ekiert
et
al
sui
et
al
bind
novel
epitop
ha
globular
head
high
frequenc
hastalk
bind
antibodi
particular
interest
epitop
promis
target
broadli
protect
influenza
vaccin
steel
et
al
furthermor
crossreact
antibodi
carri
highli
mutat
immunoglobulin
gene
indic
extens
affin
matur
togeth
find
support
model
infect
predominantli
activ
broadli
crossreact
memori
b
cell
underw
affin
matur
propos
expans
rare
type
memori
b
cell
may
explain
peopl
becom
sever
ill
even
absenc
preexist
protect
antibodi
titer
recent
studi
mice
strongli
support
idea
consecut
immun
antigen
diverg
influenza
stain
inde
hone
antibodi
respons
preferenti
target
broadli
protect
conserv
epitop
wei
et
al
find
demonstr
crossreact
antibodi
preferenti
induc
human
given
right
immunogen
provid
support
feasibl
gener
paninfluenza
vaccin
final
vivo
challeng
experi
show
neutral
antibodi
isol
protect
mice
challeng
lethal
dose
pandem
influenza
viru
even
administ
therapeut
h
infect
also
provid
protect
antigen
distinct
influenza
strain
antibodi
thu
promis
therapeut
pandem
well
activ
pandem
infect
consist
frequenc
plasmablast
secret
antibodi
bind
annual
influenza
strain
elispot
analys
fig
c
major
pandem
antibodi
also
crossreact
season
influenza
virus
fig
b
fact
elisa
one
third
antibodi
bind
prepandem
strain
lower
concentr
pandem
strain
suggest
higher
avid
bind
comparison
plasmablast
induc
annual
strain
pandem
could
bind
pandem
influenza
fig
b
propos
crossreact
pandem
cell
deriv
activ
memori
cell
origin
specif
past
influenza
immun
origin
antigen
sin
fashion
base
induct
plasmablast
express
intracellular
ongo
immun
respons
brokstad
et
al
bernasconi
et
al
sasaki
et
al
smith
et
al
wrammert
et
al
assum
plasmablast
result
ongo
infect
sort
cell
defin
high
high
cell
fig
e
wrammert
et
al
smith
et
al
gene
clone
express
mab
cell
antibodi
screen
reactiv
elisa
threshold
score
antibodi
specif
influenza
antigen
empir
determin
base
two
standard
deviat
greater
background
level
bind
evid
naiv
b
cell
antibodi
fig
antibodi
gener
fashion
bound
pandem
fig
f
one
third
antibodi
reactiv
ha
fig
g
fig
subnanomolar
avid
base
surfac
plasmon
reson
analys
fig
b
per
donor
basi
mab
bound
purifi
pandem
virion
rang
virusspecif
antibodi
bound
recombin
ha
rang
conclud
virusspecif
plasmablast
readili
detect
pandem
influenza
viru
infect
virusspecif
human
mab
effici
gener
cell
plasmablast
patient
infect
pandem
influenza
highli
crossreact
prepandem
influenza
strain
plasmablast
specif
induc
ongo
immun
respons
learn
origin
b
cell
mab
column
indic
whether
mab
made
plasmablast
patient
tabl
mutat
accumul
significantli
lower
frequenc
igg
control
fig
p
suggest
uniqu
circumst
lowlevel
lack
primari
respons
detail
sequenc
characterist
pandem
plasmablast
provid
tabl
though
base
limit
vaccin
respons
readi
detect
clonal
expans
mean
frequenc
cell
six
patient
support
view
base
sequenc
similar
fig
c
sinc
discoveri
somat
mutat
appreci
mutat
progress
accumul
variabl
gene
repeat
immun
mckean
et
al
thu
gain
insight
origin
pandem
respons
compar
somat
mutat
frequenc
plasmablast
present
infect
plasmablast
respons
pcr
strategi
allow
isol
either
igg
iga
transcript
identifi
igg
iga
plasmablast
patient
similar
plasmablast
induc
annual
vaccin
wrammert
et
al
fourth
booster
vaccin
anthrax
variabl
gene
novel
cell
five
six
patient
harbor
high
number
somat
mutat
antibodi
test
threefold
serial
dilut
nonbind
concentr
determin
antibodi
test
least
two
typic
replic
specif
affin
estim
note
habind
antibodi
curv
g
one
hareact
antibodi
bind
ha
whole
virion
recombin
protein
reactiv
mab
isol
infect
patient
em
assay
bind
annual
influenza
strain
whole
viru
minimum
detect
concentr
defin
two
standard
deviat
mean
bind
randomli
chosen
naiv
b
cell
antibodi
fig
bar
color
code
approxim
level
crossreact
annual
vaccin
circul
strain
recent
year
panel
b
use
color
scheme
valu
repres
least
two
replic
elisa
repeat
singl
consist
minimum
concentr
establish
center
numer
equal
total
antibodi
c
analysi
variabl
gene
sequenc
plasmablast
four
pandem
patient
indic
pandem
plasmablast
clonal
relat
share
ident
vh
jh
gene
junction
averag
number
somat
hypermut
pandem
patient
plasmablast
variabl
region
gene
compar
primari
igg
plasmablast
respons
vaccinia
small
pox
anthrax
vaccin
least
booster
anthrax
vaccin
account
obviou
outlier
pandem
group
patientem
median
valu
indic
bar
student
test
exclud
outlier
indic
pvalu
remain
five
pandem
sampl
compar
igg
memori
germin
center
gc
cell
primari
igg
plasmablast
respons
em
includ
pvalu
igm
popul
notabl
besid
patient
em
individu
set
vh
gene
averag
significantli
mutat
igg
memori
gc
primari
respons
fig
point
repres
one
individu
donor
averag
sequenc
except
primari
respons
anthrax
vh
gene
could
clone
singl
cell
highli
limit
respons
mutat
accumul
per
individu
sequenc
depict
fig
detail
sequenc
characterist
provid
tabl
naiv
igg
igm
gc
memori
popul
deriv
histor
data
zheng
et
al
zheng
et
al
koelsch
et
al
wrammert
et
al
indic
bound
site
ha
activ
site
interestingli
antibodi
latter
type
predomin
respons
fig
specif
reminisc
antibodi
recent
discov
broadli
neutral
epitop
found
ha
stalk
rather
locat
ha
globular
head
typic
neutral
antibodi
ekiert
et
al
sui
et
al
importantli
five
antibodi
inde
similar
specif
includ
antibodi
clonal
pair
donor
five
antibodi
bind
high
affin
strain
includ
vaccin
past
yr
pandem
strain
highli
pathogen
number
patient
frequent
crossreact
high
number
somat
mutat
support
model
mani
plasmablast
induc
pandem
infect
aros
crossreact
memori
b
cell
major
neutral
antibodi
bound
highli
conserv
epitop
ha
stalk
head
region
high
frequenc
haspecif
antibodi
abl
neutral
viru
vitro
total
fig
neutral
antibodi
could
categor
two
distinct
group
neutral
antibodi
display
hemagglutin
inhibit
hai
activ
hai
b
neutral
antibodi
hai
activ
fig
antibodi
group
base
whether
show
hai
andor
neutral
neut
function
antibodi
test
bind
whole
viru
antibodi
bind
rha
due
bind
quaternari
conform
sensit
epitop
present
recombin
protein
hai
neutral
assay
perform
duplic
repeat
least
three
time
elisa
curv
provid
fig
b
elisa
bind
shown
minimum
posit
concentr
defin
fig
neutral
mab
rha
whole
virion
pandem
influenza
strain
elisa
bind
curv
provid
fig
three
bind
pattern
epitop
observ
coincid
specif
comparison
competit
elisa
illustr
fig
c
three
repres
neutral
antibodi
use
hai
microneutr
mn
activ
pandem
sever
annual
laboratori
influenza
strain
experi
perform
duplic
repeat
least
three
time
minimum
effect
concentr
shown
assay
fac
analysi
show
five
antibodi
bound
variant
test
level
quit
similar
crystal
structur
gener
defin
epitop
thu
half
neutral
surpris
antibodi
induc
pandem
infect
bound
conserv
critic
epitop
ha
stalk
comparison
none
strainspecif
antibodi
previous
isol
annual
vaccin
pandem
reactiv
unpublish
data
frequenc
pandemicinduc
stemreact
antibodi
versu
annual
vaccin
significantli
greater
chisquar
test
p
specif
rare
seen
human
memori
b
cell
corti
et
al
phagedisplay
librari
sui
et
al
observ
support
avian
influenza
strain
fig
b
fig
addit
five
antibodi
crosscompet
similar
epitop
overlap
hai
antibodi
fig
antibodi
competit
inhibit
commerci
antibodi
refer
bind
ha
stalk
region
okuno
et
al
four
five
antibodi
encod
hallmark
gene
ekiert
et
al
sui
et
al
verifi
ha
stalk
reactiv
five
antibodi
test
bind
variant
predict
affect
stalk
epitop
crystal
structur
bind
pattern
compar
prototyp
stalk
antibodi
mab
sui
et
al
fig
b
variant
singl
residu
mutat
stalk
region
transient
express
cell
competit
elisa
assay
use
determin
similar
specif
variou
neutral
antibodi
shown
percentag
competit
antibodi
elisa
bind
assay
neutral
antibodi
molar
excess
unlabel
antibodi
use
inhibit
biotinyl
antibodi
percent
competit
calcul
reduct
absorb
rel
level
inhibit
particular
antibodi
color
indic
degre
inhibit
antibodi
bind
indic
antibodi
commerci
antibodi
bind
stalk
region
ha
molecul
identifi
hahead
activ
site
nonneutr
habind
antibodi
competit
hareact
antibodi
therefor
shown
vh
gene
usag
individu
antibodi
list
right
assay
perform
duplic
b
plasmid
encod
fulllength
wt
mutant
transient
transfect
cell
h
transfect
cell
harvest
fac
analysi
bind
indic
antibodi
test
cell
surfac
ha
express
mutant
verifi
ferret
serum
depict
antibodi
one
antibodi
use
character
ha
stalk
epitop
xray
crystallographi
sui
et
al
serv
posit
control
bind
pattern
expect
ha
stalkreact
antibodi
ha
mutant
recent
vaccin
strain
react
strongli
pandem
strain
antibodi
fig
b
fig
mab
bind
past
vaccin
strain
higher
avid
pandem
studi
underway
precis
identifi
epitop
neutral
antibodi
studi
two
neutral
antibodi
highli
specif
pandem
strain
alon
fig
b
fig
includ
low
avid
antibodi
show
slight
neutral
capac
vitro
effect
neutral
pandem
influenza
conclud
experi
surpris
neutral
plasmablast
isol
pandem
influenza
infect
broadli
crossreact
multipl
influenza
strain
distinct
interest
develop
monoclon
antibodi
use
therapeut
set
select
three
repres
antibodi
set
identifi
detail
function
analysi
vitro
fig
c
vivo
fig
fig
includ
antibodi
specif
activ
site
ha
molecul
wherea
bind
stalk
region
furthermor
highli
specif
pandem
wherea
display
idea
vaccin
might
develop
preferenti
target
ha
stalk
thu
provid
broad
protect
mani
influenza
strain
remain
neutral
antibodi
hai
therefor
bound
ha
globular
head
base
crosscompetit
analys
antibodi
fell
two
group
bind
nonoverlap
region
ha
head
includ
fig
b
fig
inde
use
spontan
escap
mutant
select
found
mab
bind
sa
region
ha
globular
head
unpublish
data
thu
proxim
base
competit
assay
fig
predict
antibodi
bind
near
sasb
region
includ
broadli
reactiv
antibodi
bind
pandem
strain
common
annual
strain
identifi
human
xu
et
al
mice
manicassami
et
al
notabl
three
five
ha
globularheadbind
antibodi
induc
pandem
infect
also
broadli
reactiv
variou
strain
fig
b
one
novel
antibodi
antibodi
react
strongli
pandem
strain
well
recent
vaccin
strain
fig
b
fig
precis
epitop
antibodi
bind
appear
quit
uniqu
access
whole
virion
recombin
ha
suggest
epitop
quaternari
natur
final
two
antibodi
crossreact
inhibit
hemagglutin
figur
vivo
prophylact
therapeut
efficaci
human
mab
pandem
influenza
viru
balbc
mice
infect
dose
highli
pathogen
mouseadapt
pandem
influenza
acalifornia
h
infect
mgkg
bodi
weight
human
mab
inject
intraperiton
mice
monitor
daili
bodi
weight
chang
sign
morbid
mortal
percentag
initi
bodi
weight
plot
number
surviv
mice
shown
lower
right
plot
infect
untreat
mice
show
clear
sign
sick
around
day
infect
perish
day
prophylact
treatment
shown
left
comparison
antibodi
treatment
confer
signific
protect
determin
comparison
weight
untreat
versu
prophylaxi
time
treatment
versu
infect
unpair
twotail
student
test
p
logrank
test
indic
signific
surviv
well
p
figur
show
one
repres
experi
least
three
independ
repeat
experi
pandem
protect
effect
infect
conclus
antibodi
character
herein
show
promis
develop
broadli
reactiv
therapeut
agent
pandem
influenza
viru
well
major
influenza
strain
find
provid
insight
human
b
cell
respons
pandem
influenza
viru
strain
uniqu
genet
composit
pandem
influenza
viru
meant
rel
young
cohort
probabl
littl
preexist
specif
antibodymedi
immun
viru
infect
brockwellstaat
et
al
dawood
et
al
garten
et
al
hancock
et
al
thu
two
sourc
b
cell
could
contribut
respons
newli
recruit
naiv
b
cell
preexist
memori
b
cell
bound
epitop
conserv
past
season
strain
pandem
strain
theoriz
predomin
activ
latter
preexist
memori
cell
account
observ
high
frequenc
neutral
antibodi
habind
antibodi
major
crossreact
season
strain
fig
c
group
influenza
strain
includ
ha
sever
observ
support
conjectur
convincingli
particularli
high
frequenc
crossreact
antibodi
overal
high
level
somat
mutat
found
particularli
among
variabl
gene
crossreact
cell
fig
fig
fact
elisa
antibodi
crossreact
one
third
broadli
crossreact
bind
fig
b
function
activ
multipl
recent
older
strain
fig
c
antibodi
highli
effect
provid
prophylact
protect
infect
lethal
dose
mouseadapt
pandem
balbc
mice
fig
moreov
three
antibodi
effect
therapeut
even
administ
late
h
lethal
challeng
infect
well
mice
symptomat
success
treat
mice
far
h
postinfect
unpublish
data
infect
mice
alreadi
show
measur
weight
loss
revers
administr
antibodi
demonstr
therapeut
potenti
even
onset
diseas
viral
clearanc
analyz
mice
treat
h
infect
fig
earli
day
antibodytr
mice
exhibit
log
reduct
viral
titer
titer
continu
declin
day
viru
undetect
present
low
level
untreat
mice
perish
day
wherea
treat
mice
clear
infect
detect
viru
day
final
show
activ
sever
current
older
season
influenza
strain
vitro
fig
c
also
test
vivo
antigen
distinct
influenza
strain
experi
mice
treat
mab
intraperiton
h
infect
lethal
dose
either
pandem
influenza
either
two
common
influenza
laboratori
strain
show
protect
antigen
distinct
influenza
strain
illustr
fig
highli
specif
figur
breadth
vivo
prophylact
efficaci
mice
balbc
mice
treat
mgkg
bodi
weight
human
mab
intraperiton
control
mice
treat
pb
control
mab
polyclon
human
igg
h
later
challeng
dose
mous
adapt
pandem
influenza
viru
mice
monitor
daili
bodi
weight
chang
sign
morbid
mortal
percentag
initi
bodi
weight
left
surviv
curv
right
plot
infect
untreat
mice
show
clear
sign
sick
infect
perish
day
figur
show
one
repres
experi
least
three
independ
repeat
experi
antibodi
treatment
confer
signific
protect
determin
comparison
weight
untreat
versu
prophylaxi
time
treatment
versu
infect
unpair
twotail
student
test
p
logrank
test
indic
signific
surviv
well
p
seroconvers
presenc
highli
potent
antibodi
whose
activ
less
like
titer
highli
specif
natur
respons
patient
may
contribut
advantag
ultim
better
target
epitop
pandem
strain
contrast
patient
rel
low
hai
mn
serum
titer
highest
frequenc
broadli
neutral
antibodi
less
sever
diseas
cours
one
possibl
sampl
patient
done
peak
serolog
respons
anoth
possibl
high
frequenc
potent
antibodi
memori
b
cell
compart
may
result
rapid
resolut
infect
preclud
develop
high
serolog
respons
third
possibl
despit
broader
protect
stalkreact
antibodi
whole
less
potent
rapidli
titrat
highli
specif
antibodi
ha
globular
head
variou
possibl
signific
interest
studi
futur
final
report
develop
larg
panel
human
mab
induc
pandem
infect
prophylact
therapi
polyclon
mab
success
use
rsv
rabi
hepat
b
varicella
case
influenza
mab
shown
provid
prophylact
therapeut
protect
mice
anim
model
reuman
et
al
sweet
et
al
palladino
et
al
renegar
et
al
passiv
transfer
matern
antibodi
human
also
shown
confer
protect
puck
et
al
sever
antibodi
isol
broad
neutral
capac
vitro
diverg
influenza
strain
show
potent
prophylact
therapeut
activ
use
treat
mice
lethal
infect
influenza
antibodi
could
provid
much
need
pandem
therapeut
treat
sever
case
influenza
protect
highrisk
popul
conclus
analys
mab
induc
pandem
infect
indic
frequent
activ
broadli
reactiv
b
cell
propos
cell
memori
cell
origin
caus
crossreact
conserv
function
import
epitop
true
import
character
efficaci
pandem
vaccin
induc
similarli
crossprotect
respons
studi
approv
emori
univers
univers
chicago
columbia
univers
institut
review
board
emori
irb
u
c
irb
cu
irb
patient
clinic
inform
detail
tabl
pbmc
plasma
isol
work
sampl
infect
patient
perform
design
facil
emori
univers
peripher
blood
mononuclear
cell
pbmc
isol
use
vacutain
tube
bd
wash
resuspend
pb
fc
immedi
use
frozen
subsequ
analysi
plasma
sampl
save
frozen
medium
dimethyl
sulfoxid
subsequ
analysi
virus
antigen
pandem
influenza
viru
acalifornia
provid
rj
webbi
st
jude
children
hospit
memphi
tn
influenza
viru
stock
use
assay
freshli
grown
egg
antibodi
bound
past
annual
viral
antigen
lower
concentr
suggest
higher
avid
past
influenza
strain
current
pandem
viru
crossreact
cell
bind
higher
affin
pandem
strain
also
highest
frequenc
variablegen
mutat
fig
b
antibodi
broadli
crossreact
among
highli
mutat
clone
fig
b
propos
mani
cell
specif
crossreact
epitop
present
annual
influenza
strain
underw
affin
matur
adapt
infect
pandem
viru
support
conjectur
corti
et
al
first
demonstr
natur
occur
ha
stalkreact
memori
b
cell
could
isol
blood
peopl
recent
immun
annual
vaccin
outbreak
pandem
natur
studi
screen
ebvtransform
memori
cell
line
thu
preclud
determin
precis
frequenc
stalkreact
b
cell
howev
antibodi
estim
quit
rare
occur
one
thousand
one
hundr
influenzabind
b
cell
vari
individu
contrast
show
plasmablast
activ
infect
highli
novel
pandem
influenza
strain
substanti
increas
target
ha
stalk
region
epitop
total
influenzaspecif
antibodi
half
neutral
antibodi
fig
fact
specif
antibodi
isol
studi
crossreact
past
influenza
strain
collect
data
describ
support
model
diverg
virus
conserv
critic
region
function
elicit
higher
proport
crossreact
neutral
antibodi
thu
although
activ
plasmablast
rel
patient
could
analyz
detail
monoclon
antibodi
level
proffer
proper
immunogen
longsought
develop
paninfluenza
vaccin
might
possibl
interestingli
highli
specif
antibodi
deriv
patient
sever
diseas
cours
persist
viral
shed
sever
week
addit
variabl
gene
plasmablast
patient
lowest
averag
number
somat
mutat
fig
b
outlier
fig
b
collect
uniqu
specif
pandem
low
level
somat
mutat
unusu
sever
diseas
absenc
predispos
condit
suggest
patient
may
mount
primari
immun
respons
pandem
influenza
infect
complet
lack
preexist
immun
may
contribut
sever
diseas
observ
patient
contrast
activ
broadli
crossneutr
memori
b
cell
immun
experi
annual
strain
might
contribut
less
sever
diseas
infect
patient
pandem
notabl
discrep
patient
serum
mn
titer
sever
diseas
frequenc
plasmablast
express
neutral
antibodi
tabl
fig
exampl
patient
em
despit
worst
diseas
cours
greatest
hai
mn
serum
titer
may
caus
time
infect
day
allow
full
condit
previous
publish
wrammert
et
al
smith
et
al
variabl
gene
determin
use
inhous
analysi
softwar
compar
immunogent
v
gene
dataset
imgt
search
engin
ehrenmann
et
al
lefranc
et
al
background
mutat
rate
method
baseexchang
per
base
sequenc
base
sequenc
constant
region
gene
segment
comparison
made
histor
data
previous
publish
zheng
et
al
wrammert
et
al
duti
et
al
plaqu
assay
prnt
assay
mdck
cell
grown
plate
densiti
well
next
day
cell
wash
pb
dilut
viru
ad
dme
incub
h
mix
everi
min
cell
wash
pb
overlay
media
contain
agaros
seakem
antibiot
uml
penicillin
mgml
streptomycin
bsa
sigmaaldrich
tpcktrypsin
sigmaaldrich
cell
incub
h
fix
pfa
min
agaros
plug
remov
cell
stain
crystal
violet
etoh
min
remov
crystal
violet
solut
plate
dri
use
count
plaqu
well
prnt
assay
mdck
cell
prepar
next
day
mab
threefolddilut
pfu
viru
dme
incub
equal
volum
dilut
mab
h
plaqu
assay
plaqu
count
final
concentr
antibodi
reduc
plaqu
pfu
score
prnt
determin
tcid
mdck
cell
grown
plate
densiti
well
next
day
cell
wash
pb
dilut
virus
dme
ad
well
incub
h
incub
cell
wash
pb
dme
contain
antibiot
uml
penicillin
mgml
streptomycin
bsa
sigmaaldrich
tpcktrypsin
sigmaaldrich
ad
cell
incub
h
supernat
incub
equal
volum
pbswash
turkey
red
blood
cell
rockland
immunochem
min
four
replic
perform
dilut
complet
agglutin
score
ha
viru
titer
calcul
reedmuench
method
mn
assay
tcid
viru
dme
incub
threefolddilut
antibodi
h
cell
wash
incub
media
describ
hai
assay
h
mn
titer
determin
final
concentr
mab
complet
inhibit
infect
hai
elisa
assay
whole
viru
recombin
ha
vaccinespecif
elisa
perform
start
concentr
viru
recombin
ha
dilut
vaccin
previous
describ
wrammert
et
al
brief
microtit
plate
coat
live
viru
strain
total
hau
total
viru
per
well
recombin
ha
protein
standard
variou
elisa
assay
common
highaffin
antibodi
similar
affin
bind
characterist
viru
strain
includ
plate
plate
develop
absorb
control
reach
od
unit
goat
antihuman
igg
goat
antihuman
iperoxidaseconjug
jackson
immunoresearch
laboratori
use
detect
bind
recombin
antibodi
follow
develop
horseradish
peroxidas
substrat
biorad
laboratori
absorb
measur
micropl
reader
invitrogen
affin
estim
calcul
nonlinear
regress
analysi
curv
eight
dilut
antibodi
ugml
use
graphpad
prism
hai
titer
determin
previous
describ
wrammert
et
al
brief
sampl
serial
dilut
pb
vbottom
plate
hau
determin
incub
turkey
rbc
absenc
serum
live
egggrown
viru
ad
well
min
room
temperatur
turkey
rbc
prepar
purifi
previous
describ
wrammert
et
al
hemagglutin
inhibit
activ
determin
use
turkey
red
blood
cell
lampir
biolog
laboratori
previous
describ
wrammert
et
al
elispot
assay
direct
elispot
enumer
number
either
total
iggsecret
pandem
influenzaspecif
vaccinespecif
plasmablast
present
pbmc
sampl
essenti
done
previous
describ
crotti
et
al
brief
elispot
filter
plate
millipor
coat
overnight
either
optim
amount
purifi
pandem
virion
recombin
ha
pandem
influenza
vaccin
dilut
pb
goat
antihuman
ig
invitrogen
plate
wash
block
incub
rpmi
contain
fc
h
purifi
extens
wash
pbmc
sort
plasmablast
ad
plate
dilut
seri
incub
h
plate
wash
pb
follow
pb
contain
tween
incub
biotinyl
antihuigg
antibodi
invitrogen
incub
h
room
temperatur
wash
plate
incub
avidindhrp
conjug
vector
laboratori
final
develop
use
aec
substrat
ethylcarbazol
sigmaaldrich
develop
plate
scan
analyz
use
autom
elispot
counter
cellular
technolog
ltd
flow
cytometri
analysi
cell
sort
analyt
flow
cytometri
analysi
perform
whole
blood
lysi
erythrocyt
fix
pfa
live
cell
sort
singl
cell
sort
perform
purifi
pbmc
use
either
facsvantag
ariaii
cell
sorter
system
follow
antibodi
analyt
cell
sort
cytometri
purchas
bd
except
purchas
ebiosci
percp
percp
asc
gate
isol
high
high
cell
flow
cytometri
data
analyz
use
flowjo
softwar
gener
mab
identif
antibodi
variabl
region
gene
done
essenti
previous
describ
smith
et
al
wardemann
et
al
wrammert
et
al
brief
singl
asc
sort
pcr
plate
contain
rnase
inhibitor
promega
vh
gene
cell
amplifi
rtpcr
nest
pcr
reaction
use
cocktail
primer
specif
igg
iga
use
primer
set
detail
smith
et
al
sequenc
gener
recombin
antibodi
restrict
site
incorpor
pcr
primer
particular
variabl
junction
gene
vh
gene
amplifi
singl
cell
clone
express
vector
previous
describ
wardemann
et
al
wrammert
et
al
smith
et
al
antibodi
sequenc
deposit
genbank
access
no
avail
genbankemblddbj
heavylight
chain
plasmid
cotransfect
cell
line
express
antibodi
purifi
protein
sepharos
antibodi
protein
gener
studi
provid
limit
quantiti
upon
request
mutat
analysi
antibodi
induc
plasmablast
variabl
gene
amplifi
singlecel
rtpcr
use
primer
set
pcr
efficaci
mab
mice
treat
intraperiton
mgkg
bodi
weight
specif
mab
h
later
mice
challeng
one
mous
adapt
influenza
virus
use
studi
mice
monitor
daili
sign
morbid
mortal
bodi
weight
chang
regist
daili
period
mice
lost
initi
bodi
weight
sacrif
accord
institut
anim
care
use
committe
guidelin
determin
therapeut
efficaci
mab
mice
challeng
mouseadapt
pandem
viru
variou
time
infect
h
mice
treat
intraperiton
mgkg
bodi
weight
specif
mab
mice
monitor
daili
bodi
weight
chang
regist
daili
describ
statist
analysi
data
collect
graph
use
ms
excel
graphpad
prism
softwar
efficaci
therapeut
challeng
experi
evalu
analysi
varianc
use
graphpad
prism
softwar
onlin
supplement
materi
fig
show
bind
characterist
control
mab
fig
show
bind
characterist
neutral
mab
fig
show
analysi
pandem
plasmablast
somat
mutat
fig
show
experi
demonstr
therapeut
control
pandem
viral
titer
lung
mab
treatment
tabl
provid
detail
characterist
concern
variabl
gene
sequenc
clone
pandem
induc
plasmablast
onlin
supplement
materi
avail
http
wwwjemorgcgi
